A/Prof Nick Pavlakis graduated in 1991 after medical training at the University of NSW. He then underwent general medical training and subsequent advanced training in Medical Oncology at Royal North Shore Hospital, completing FRACP in 1997. He then spent 3 years completing a PhD in new cancer drug development involving an Australian developed anti-angiogenic compound PI-88 (Progen Industries and ANU); and completed a Masters of Clinical Epidemiology through the University of Sydney. He has worked in private oncology practice since 1998 and has been a practice member of the Northern Cancer Institute since 2001, now Genesis Care. He is current President of the Clinical Oncology Society for Australia (COSA), and Regent for Australasia for the International Association for the Study of Lung Cancer (IASLC). He is an academic medical oncologist, having published journal manuscripts in his current key interest areas (lung cancer, mesothelioma, NETs, gastric and pancreas cancers), is conducting ongoing collaborative clinical research with AGITG, The Thoracic Oncology Group of Australasia (formerly with ALTG) and translational research in the Bill Walsh Cancer Research Laboratories/Kolling Institute.
Abstracts this author is presenting: